Radiopharm Theranostics Ltd Financials
Radiopharm Theranostics Ltd (RADX) reported $3.6M in revenue for fiscal year 2025, up 1114.3% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
External funding remains the operating engine: revenue growth is not yet translating into self-funded operations.
Revenue expanded 12.1x from FY2024 to FY2025, reaching$3.6M . Yet operating cash flow deteriorated from-$23.0M to-$36.6M ; the larger sales base is not yet absorbing the company’s cash demands.
Equity rose to
The net loss narrowed by
Financial Health Signals
Radiopharm Theranostics Ltd does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Radiopharm Theranostics Ltd passes 4 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 2 of 4 profitability signals pass, all 1 leverage/liquidity signals pass, both operating efficiency signals pass.
Radiopharm Theranostics Ltd reported a net loss of $38.3M while operations used $36.6M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Radiopharm Theranostics Ltd generated $3.6M in revenue in fiscal year 2025. This represents an increase of 1114.3% from the prior year.
Radiopharm Theranostics Ltd reported -$38.3M in net income in fiscal year 2025. This represents an increase of 20.0% from the prior year.
Radiopharm Theranostics Ltd earned $1000000.00 per diluted share (EPS) in fiscal year 2025. That is unchanged from the prior year.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Radiopharm Theranostics Ltd held $29.1M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
Radiopharm Theranostics Ltd's ROE was -89.4% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 85.9 percentage points from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
None of these metrics is reported for fiscal year 2025.
RADX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q4'25 | Q4'24 |
|---|
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, R&D Expenses, SG&A Expenses, Operating Income, Interest Expense, Income Tax, Net Income, EPS (Diluted).
RADX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q4'25 | Q4'24 |
|---|---|---|
| Total Assets | $86.5M+20.1% | $72.0M |
| Current Assets | $39.9M+74.4% | $22.8M |
| Cash & Equivalents | $29.1M+56.8% | $18.6M |
| Accounts Receivable | $10.4M+953.3% | $987K |
| Total Liabilities | $43.6M-2.4% | $44.7M |
| Current Liabilities | $14.9M-15.0% | $17.6M |
| Total Equity | $42.9M+56.7% | $27.4M |
Not reported in any period shown, so not listed: Inventory, Goodwill, Long-Term Debt, Retained Earnings.
RADX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q4'25 | Q4'24 |
|---|
Not reported in any period shown, so not listed: Operating Cash Flow, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Financing Cash Flow, Dividends Paid, Share Buybacks.
RADX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | Q4'25 | Q4'24 |
|---|---|---|
| Current Ratio | 2.67+1.4x | 1.30 |
| Debt-to-Equity | 1.02-0.6x | 1.63 |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Equity, Return on Assets, FCF Margin.
Similar Companies
Where Radiopharm Theranostics Ltd Ranks
Frequently Asked Questions
What is Radiopharm Theranostics Ltd's annual revenue?
Radiopharm Theranostics Ltd (RADX) reported $3.6M in total revenue for fiscal year 2025. This represents a 1114.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Radiopharm Theranostics Ltd's revenue growing?
Radiopharm Theranostics Ltd (RADX) revenue grew by 1114.3% year-over-year, from $299K to $3.6M in fiscal year 2025.
Is Radiopharm Theranostics Ltd profitable?
No, Radiopharm Theranostics Ltd (RADX) reported a net income of -$38.3M in fiscal year 2025.
What is Radiopharm Theranostics Ltd's return on equity (ROE)?
Radiopharm Theranostics Ltd (RADX) has a return on equity of -89.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Radiopharm Theranostics Ltd's operating cash flow?
Radiopharm Theranostics Ltd (RADX) recorded an outflow of $36.6M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Radiopharm Theranostics Ltd's total assets?
Radiopharm Theranostics Ltd (RADX) had $86.5M in total assets as of fiscal year 2025, including both current and long-term assets.
What is Radiopharm Theranostics Ltd's current ratio?
Radiopharm Theranostics Ltd (RADX) had a current ratio of 2.67 as of fiscal year 2025, which is generally considered healthy.
What is Radiopharm Theranostics Ltd's debt-to-equity ratio?
Radiopharm Theranostics Ltd (RADX) had a debt-to-equity ratio of 1.02 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Radiopharm Theranostics Ltd's return on assets (ROA)?
Radiopharm Theranostics Ltd (RADX) had a return on assets of -44.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Radiopharm Theranostics Ltd's Piotroski F-Score?
Radiopharm Theranostics Ltd (RADX) has a Piotroski F-Score of 4 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Radiopharm Theranostics Ltd's earnings high quality?
Radiopharm Theranostics Ltd (RADX) reported a net loss of $38.3M while operations used $36.6M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.